GLP-1/GIP receptor co-agonism — anyone have experience?

Dr.ReproEndo said:

If two explanations both fit, the useful question is which one predicts something the other does not.

Coming at Dr.ReproEndo’s question from a different direction. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

One thing that is still open after Dr.ReproEndo’s answer:

How long did you give it before you decided it was working?

Dr.GutHealth said:

Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

Dr.GutHealth said:

Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Ask again with the specifics and you will get a better answer than this one.